Family History May Be Key To Wider Adoption Of Genetic Screening
This article was originally published in The Gray Sheet
Executive Summary
Before the market for genetic screening tests can take off, health care providers must do a better job of collecting their patients' family history, according to experts speaking May 6 at CMS headquarters in Baltimore
You may also be interested in...
News In Brief
BD sells bulk of labware biz to Corning. HHS proposes delay in ICD-10 implementation. New Hampshire legislation would outlaw physician-owned distributors in the state. More news briefs.
Reimbursement In Brief
MedCAC pharmacogenomics meeting: The Medicare Evidence Development and Coverage Advisory Committee will meet Jan. 27, 2010, in Baltimore to review evidence on the impact of pharmacogenomic testing on health outcomes in cancer patients. Specifically, the panel will assess assays that might be used as a guide for certain drug treatments for breast cancer, colon cancer, chronic myelogenous leukemia or metastatic colorectal cancer. The upcoming meeting is the third in a series of MedCAC discussions held this year on evidence supporting genetic and genomic screening (1"The Gray Sheet" May 25, 2009)
Reimbursement In Brief
MedCAC pharmacogenomics meeting: The Medicare Evidence Development and Coverage Advisory Committee will meet Jan. 27, 2010, in Baltimore to review evidence on the impact of pharmacogenomic testing on health outcomes in cancer patients. Specifically, the panel will assess assays that might be used as a guide for certain drug treatments for breast cancer, colon cancer, chronic myelogenous leukemia or metastatic colorectal cancer. The upcoming meeting is the third in a series of MedCAC discussions held this year on evidence supporting genetic and genomic screening (1"The Gray Sheet" May 25, 2009)